From Dog

Toceranib is a synthetic protein kinase inhibitor drug, thought to act through inhibition of the kit tyrosine kinase, though it may also have an anti-angiogenic effects.

Toceranib phosphate was developed for use against grade 2 and grade 3 mast cell tumors[1] and thyroid carcinoma, but has also been trialed experimentally with anal sac adenocarcinoma.

Levels of interferon are significantly increased in dogs receiving chemotherapy with toceranib in conjunction with drugs such as cyclophosphamide[2].

Side effects of toceranib use include diarrhea, anorexia, lameness and melena.

Recommended dose in dogs is 2.8 mg/kg daily.


  1. London CA et al (2009) Multi-center, placebo-controlled, double-blind, randomized study of oral toceranib phosphate (SU11654), a receptor tyrosine kinase inhibitor, for the treatment of dogs with recurrent (either local or distant) mast cell tumor following surgical excision. Clin Can Res 15(11):3856-3865
  2. Mitchell L et al (2012) Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. J Vet Intern Med 26(2):355-362